39 results about "Ketotifen" patented technology

Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and / or ketotifen. Embodiments of the composition are administered, for example, by injection, and / or transdermally.

The present invention provides topical formulations of ketotifen that provide a comfortable formulation when instilled in the eye and are effective in the treatment and prevention of ocular allergy, particularly allergic conjunctivitis. The invention further provides methods of treating and preventing ocular allergy by in a subject in need of such treatment by topical application of the ketotifen formulations of the invention to the eye of a subject in need thereof.

The present invention relates to methods of prophylactically treating, reducing, delaying or controlling severe allergic reaction, e.g., to food and / or hymenoptera allergen, e.g. peanut allergen or bee venom allergen, in patients at risk of systemic anaphylaxis, e.g., patients receiving allergen desensitization therapy, through the use of a mast cell stabilizer, e.g., ketotifen and / or its metabolites or derivatives in free or pharmaceutically acceptable acid addition salts thereof. The invention further provides methods to desensitize a patient to one or more allergens comprising administering (i) one or more allergen to induce tolerance and (ii) one or more mast cell stabilizers in free or pharmaceutically acceptable salt thereof.

The invention provides a package for storing medical devices that substantially eliminates elution of a pharmaceutical agent, from the device into the package. As well, a new lidstock is described for use with the package, which results in better retention of drug throughout the bowl and lidstock.

The invention relates to an H1-receptor-antagonist-containing inhalation preparation which contains an H1 receptor antagonist and one or more pharmaceutical auxiliary materials suitable for inhalation administration. The H1 receptor antagonist is one or more of loratadine, desloratadine, cetirizine, levocetirizine, astemizole, ketotifen, ebastine, fexofenadine, avastin, mequitazine, mizolastine and salts thereof, and preferably one or more of loratadine, desloratadine, cetirizine, levocetirizine, ebastine, mizolastine, avastin, mequitazine, ketotifen and hydrochlorides or fumarates thereof.

The invention relates to a pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) a chemotherapeutic drug subject to multi-drug resistance by P-gp, such as doxorubicin or an analog thereof. The pharmaceutical composition is useful for treating cancer. The pharmaceutical composition is also useful for i) preventing or treating multi-drug resistance in a subject or ii) preventing a chemotherapeutic drug subject to multi-drug resistance by P-gp induced cardiac tissue damage in a subject, such as doxorubicin or an analog thereof. The invention relates to a pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) a chemotherapeutic drug subject to multi-drug resistance by P-gp, such as doxorubicin or an analog thereof. The pharmaceutical composition is useful for treating cancer. The pharmaceutical composition is also useful for i) preventing or treating multiamrg resistance in a subject or ii) preventing a chemotherapeutic drug subject to multi-drug resistance by P-gp induced cardiac tissue damage in a subject, such as doxorubicin or an analog thereof.

Ophthalmic compositions comprising ketotifen, a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w / v), one or more ocular-compatible hydrogen peroxide stabilizers, HPMC and CMC, and methods for the treatment and prevention of allergic conjunctivitis using these ophthalmic compositions are provided herein.

Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w / v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein.

The present invention provides a method of inhibiting tolerance to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.

Provided is a use of a compound capable of influencing, at least in part, an activity of a neural reflex pathway for the preparation of a medicament for altering the motility of the gastrointestinal tract. The medicament can be used for prophylaxis and / or treatment of hypomotility of the gastrointestinal tract. Preferably, generalized hypomotility occurring during postoperative ileus is prevented and / or treated by a medicament of the invention. In one aspect, the neural reflex pathway's activity is decreased by, at least in part, preventing stimulation of the pathway by an immunocyte, a macrophage and / or a mast cell. Activity can also be decreased by, at least in part, preventing immunocyte recruitment. A compound capable of, at least in part, influencing an activity of, for instance, a neural reflex pathway comprises an anti-ICAM-1 antibody, an anti LFA-1 antibody, and / or ketotifen. A pharmaceutical composition for prophylactic and / or therapeutic treatment of an individual against hypomotility of the gastrointestinal tract comprising a compound capable of, at least in part, decreasing a neural reflex pathway is also herewith provided.

The invention discloses allergy-removal rhinitis cream which is prepared from, by weight, 8-10% of astragalus membranaceus, 8-10% of codonopsis pilosula, 10-15% of scutellaria baicalensis, 3-5% of lumbricus, 3-5% of as arum, 3-5% of honeysuckle, 3-5% of menthol, 3-5% of radix aconiti carmichaeli and the balance finished product western medicine supplementary materials; the finished product western medicine supplementary materials comprise ketotifen, cyproheptadine, prednisone, chlortrimeton and magnesium sulfate; the traditional Chinese medicine is crushed and ground in proportion, the western medicine supplementary materials are crushed and ground in proportion, the traditional Chinese medicine ingredients and the western medicine supplementary materials are stirred and mixed, polyving akohol, sodium methyl cellulose and glycerinum are added and blended into a paste shape, and the allergy-removal rhinitis cream is obtained. The Chinese herbal medicine has the effects of clearing away heat and dispelling wind-evil, dispelling cold to dredge main and collateral channels, tonifying the lungs and the spleen, and nourishing the kidney and supplementing the yang; the finished product western medicine supplementary materials have the functions of inhibiting exudation of inflammation, lowering the permeability of blood capillary, resisting to histamine, acetyl choline and 5-hydroxytryptamine are achieved, cytomembranes of mast cells can be stabilized, and releasing of anaphylactic mediators is inhibited.

The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

The present invention provides a method of inhibiting tolerance to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

The invention relates to a special-effect drug for treating asthma, which is composed of a drug I, a drug II and a drug III; the drug I comprises the following components by weight: 0.016g of dead bacillus calmette guerin vaccine, 1.071g of potato starch, 0.3g of aminophylline, 0.001g of ketotifen, 0.005g of dioxopromethazine, 0.025g of levomisole, 0.03g of bromhexine and 0.8g of green tea; the drug II comprises the following components by weight: 1.4g of fructus schisandrae, 1.4g of astragalus and 0.3g of cinnamon; and the drug IIT comprises the following components by weight: 1.2g of radix codonopsis, 1.2g of astragalus, 0.3g of epimedium and 0.4g of gypsum. The special-effect drug disclosed by the invention is prepared on the basis of combination of Chinese and western medicine sciences, has remarkable treatment effect, and treats both symptoms and root causes.

The invention discloses a medicine composition for asthma treatment and a preparation method thereof.The medicine composition for asthma treatment is prepared from eburicoic acid, mangiferin, hyperoside, raffinose, isotaxiresinol, 3,4-dihydroxybenzaldehyde, geraniol, stachydrine, ketotifen, trumpet shell refined powder, heracleum repula root extract, quercetin, omega-3 fatty acid, vitamin A, vitamin C, vitamin E, a filling agent, an adhesive, a disintegrating agent and a lubricating agent.Western medicine and traditional Chinese medicine extract effective ingredients are combined, and the medicine composition has the effects of eliminating phlegm and removing stasis, resisting inflammation and anaphylaxis, achieving spasmolysis, relieving asthma and enhancing immunologic function, can relax bronchial smooth muscle, improve pulmonary ventilation and reduce airway resistance, also can restrain airway inflammation, maintain normal lung function, adjust body immunocompetence and reduce side effects of medicine, is used for preventing asthmatic attack and preventing or reducing the recurrence rate as much as possible, and achieves the purpose of consolidating treatment.

The present invention is a method of treating enteropathic arthritis in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID), and / or a salt thereof; and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.

The invention relates to a fluticasone and fluticasone ester / H1 receptor antagonist inhalant which contains fluticasone and fluticasone ester and one or more H1 receptor antagonists used as active components, and one or more pharmaceutical auxiliary materials suitable for inhalation administration. The H1 receptor antagonist is one or more of loratadine, desloratadine, cetirizine, levocetirizine, astemizole, ketotifen, ebastine, fexofenadine, avastin, mequitazine, mizolastine and salts thereof, and preferably one or more of loratadine, desloratadine, cetirizine, levocetirizine, ebastine, mizolastine, avastin, mequitazine, ketotifen and hydrochlorides or fumarates thereof.

The invention relates to the technical field of the neurology department, in particular to a medicine for treating neurasthenia. The medicine is prepared from components in percentage by mass as follows: 2%-4% of trimetozine, 1%-5% of midecamycin, 30%-40% of nabumetone, 15%-17% of taurine, 2%-6% of ketotifen, 23%-25% of catechol, 3%-5% of nicotinamide, 1%-3% of oleanolic acid, 1.5%-2.5% of quetiapine and 2.5%-11.5% of loxoprofen. The invention also discloses a preparation method of the medicine. The medicine comprises the steps as follows: step 1, preparing materials; step 2, drying and grinding the materials into powder; step 3, performing crushing treatment; step 4, preparing an ethanol solution; step 5, performing concentration and drying; step 6, extracting the medicine. The medicine can effectively improve organism functions and enhance immunity, has significant effects on the neurasthenia, has no toxic or side effects on the human body, can relieve anxiety and cognitive defect symptoms and has effects of clearing heat, reducing internal heat, regulating flow of vital energy and dredging collaterals.

The invention discloses a preparation method of nanoparticles with the functions of inhibiting histamine release and histamine receptor antagonism. The preparation method comprises the following steps: synthesizing hydroxybutyl chitosan (patent number ZL201110214776.X); grafting desalinated cetirizine to the hydroxybutyl chitosan by carbodiimide reaction to obtain cetirizine-hydroxybutyl chitosan;dissolving the cetirizine-hydroxybutyl chitosan and ketotifen into dimethyl sulfoxide; dropwise adding a mixed solution into distilled water under the stirring condition to obtain ketotifen: cetirizine-hydroxybutyl chitosan. A preparation process of the nanoparticles has the advantages of simplicity, short cycle and low cost; the nanoparticles have the effects of inhibiting the histamine releaseand histamine H1 receptor antagonism, can effectively relieve typical allergy symptoms and have a good development and application prospect on treatment aspect of allergic rhinitis.

The invention discloses a Western medicine composition for treating sciatica and application thereof. Active ingredients of the Western medicine composition consist of the following components in parts by mass: 42-49 parts of nabumetone, 13-18 parts of taurine and 9-15 parts of ketotifen. The dosage for adults is 1.1-1.3 mg of active ingredients / kg / day. The medicine composition provided by the invention takes the nabumetone, the taurine and the ketotifen as raw materials, has great therapeutic effect on the sciatica, and has an effective rate up to 96% and a total effective rate of 100% which are verified by clinic treatments; moreover, no relapse occurs after patients are recovered; the composition is safe without toxic or side effects.